Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.

People don't like online forms (gasp!). And it's not hard to see why: Online forms require extra work (and time) and typically stand in the way of a consumer's getting what he or she really wants—such ...

The latest price target for Vertex Pharmaceuticals (NASDAQ:VRTX) was reported by UBS on November 7, 2025. The analyst firm set a price target for $546.00 expecting VRTX to rise to within 12 months (a ...

NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its third quarter ended September 30, 2025 and the ...

Suzanne is a content marketer, writer, and fact-checker. She holds a Bachelor of Science in Finance degree from Bridgewater State University and helps develop content strategies. Investopedia / ...

Generic versions of biologic drugs could hit the market without human trials and allow the market forces to bring down costs, ...

BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $563 from $565 and keeps a Buy rating on the shares. The firm, which expects steady growth for the cystic fibrosis franchise in ...